Los Angeles Capital Management & Equity Research Inc. decreased its position in Diplomat Pharmacy, Inc. (NYSE:DPLO) by 21.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,420 shares of the company’s stock after selling 3,470 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Diplomat Pharmacy were worth $257,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Frontier Capital Management Co. LLC raised its holdings in Diplomat Pharmacy by 4.1% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 5,677,230 shares of the company’s stock valued at $84,023,000 after acquiring an additional 221,769 shares during the period. Janus Henderson Group PLC bought a new stake in Diplomat Pharmacy during the 2nd quarter valued at $67,476,000. Vanguard Group Inc. raised its holdings in Diplomat Pharmacy by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,077,145 shares of the company’s stock valued at $60,342,000 after acquiring an additional 210,334 shares during the period. Davis Selected Advisers raised its holdings in Diplomat Pharmacy by 4.4% during the 2nd quarter. Davis Selected Advisers now owns 1,703,992 shares of the company’s stock valued at $25,219,000 after acquiring an additional 71,846 shares during the period. Finally, State Street Corp raised its holdings in Diplomat Pharmacy by 1.7% during the 2nd quarter. State Street Corp now owns 1,265,089 shares of the company’s stock valued at $18,718,000 after acquiring an additional 20,834 shares during the period. Institutional investors and hedge funds own 72.48% of the company’s stock.
A number of equities research analysts have issued reports on the stock. Deutsche Bank assumed coverage on shares of Diplomat Pharmacy in a report on Monday. They set a “buy” rating and a $22.00 target price on the stock. Mizuho set a $16.00 target price on shares of Diplomat Pharmacy and gave the company a “hold” rating in a report on Tuesday, October 24th. TheStreet raised shares of Diplomat Pharmacy from a “d+” rating to a “c-” rating in a report on Thursday, August 10th. Zacks Investment Research raised shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, BidaskClub cut shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 17th. Six investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $20.39.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.10. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The business’s quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.21 earnings per share. research analysts expect that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current year.
In other news, President Joel Saban bought 10,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The shares were acquired at an average price of $15.24 per share, with a total value of $152,400.00. Following the completion of the purchase, the president now directly owns 12,000 shares in the company, valued at $182,880. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Atul Kavthekar bought 2,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief financial officer now owns 2,000 shares of the company’s stock, valued at $30,000. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 15,000 shares of company stock worth $228,780. Insiders own 30.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/12/05/diplomat-pharmacy-inc-dplo-shares-sold-by-los-angeles-capital-management-equity-research-inc.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.